Method of Treating Solid Cancers with Pegylated IL-10
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,364,517 | Method of treatment of lymphoma with Pegylated IL-10 In force · Medium confidence UsedRemaining | Merck Sharp & Dohme Corp. | In force | Medium confidence | ||
| US 9,833,514 | Use of Pegylated IL-10 to Treat Cancer In force · Medium confidence | Merck Sharp & Dohme Corp. | In force | Medium confidence | ||
| US 10,568,968 | Methods for Treatment of Cancer with Therapeutic Combinations Comprising PEG-IL-10 In force · Medium confidence | Merck Sharp & Dohme Corp. | In force | Medium confidence | ||
| US 8,865,652 | Method of Treating Solid Cancers with Pegylated IL-10 In force · Medium confidence | Merck Sharp & Dohme Corp. | In force | Medium confidence | ||
| Application 11/862,626 | Use of Pegylated IL-10 to Treat Cancer Abandoned Abandoned Aug 28, 2009 | Schering Corporation | Abandoned | Abandoned Aug 28, 2009 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Schering Corporation.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.